This actual case study illustrates the usefulness of the DNA fingerprinting method in biobank QC procedures and emphasises the need for detailed and accurate record keeping during processing of biological samples, and the value of independent thirdparty assessment to identify points at which errors are most likely to have occurred when unexpected results are found from biospecimens from biobanks.
Introduction
In many cases previously published scientific research results are not repeatable and the ability to confirm important new discoveries fails. It has been estimated that up to one-third of all cell lines have an origin other than that supposed [1] and research articles were published with misidentified cell lines leading to questionable results [2, 3] . Cell line contamination and authentication problem was a huge issue for many decades, since HeLa was established. A lot of discussions and publications pointed out and rehashed this old problem [4] [5] [6] . It was reported by Boonstra et al. [1] that the frequently used cell lines SEG-1, BIC-1 and the SK-GT-5 were cell lines from other tumor types and experimental results based on these contaminated cell lines have led to clinical trials recruiting patients, to more than 100 scientific publications, and to at least three National Institutes of Health cancer research grants and 11 US patents.
In the recent discussion by Reid Y. and Mintzer J. [7] the importance of this problem for biobanks has been mentioned. However, biobanks consist not only cell lines, but of different types of samples and human biological material, such as tissue, blood, extracted cells and nucleic acids, etc. Such samples are also used in wide-ranging studies designed to identify biomarkers underlying causes of diseases or the genes associated studies with a particular disease. The results of these studies can lead to the development of new treatments or development prognostic and diagnostic biomarkers. During handling and processing samples and associated data may go through plenty of procedures and techniques, which could be in different locations and performed by different individuals. Therefore it is necessary to maintain the detailed and accurate record keeping for the samples and their associated data during the processes they undergo.
Whenever a doubt related to traceability arises in a biobank it is usually very difficult to check whether a sample does belong to a specific donor, since donor is deidentified. In such case, the biobank will not be able to certify that samples are correctly supplied to research groups or any following downstream applications. It is therefore highly critical for biobanking activities to implement a quality assay/procedure to guarantee authentication of stored biospecimens.
To overcome the sample processing logistic problem, it has been proposed that each biobank uses allocated and unique structured code -the SPREC [8] , but to overcome the sample authentication problem -there is still a gap in use of QC assays for sample authentication. In this report we show a case study of biospecimen authentication from a tissue bank. However, this QC assay procedure could be applicable to any derivatives such as cell line collections or cells isolated from biological fluids, or any DNA obtained from any samples in biobanks.
In current study, a researcher using extracted nucleic acid, supplied by one of tissue banks, for an "omics" technology, reported that there appeared to be a mismatch between samples from 3 different cases. All the cases were collected in a single Institute (A) and extracted by a second Institute (B) in 2009 and 2011. Care was taken to document the extraction procedure and it was ascertained that it was unlikely that the samples had been mislabelled during the extraction process as they were extracted by different individuals on different dates.
Two possibilities therefore remained -mislabelling at the collection centre, or mislabelling at the researcher's institute. The "omics' technique involved multiple steps and there was therefore the third possible scenario -the potential mislabelling, or contamination of tubes to occur during the analysis.
Institute B had been provided with two different blocks of each of tumour and normal for two of the cases; residual DNA was available from 7 of the 8 of the FFPE blocks extracted. Residual DNA from the original extraction was also available from the 3rd case. The Integrated Biobank of Luxembourg (IBBL) agreed to act as an independent assessor and provided DNA fingerprinting on the samples.
Materials and Methods

Ethics Statement
The sample collection used in the study was approved by the Imperial College Research Ethics Committee in UK (protocol number ICREC-8-2-4) and the U.S. National Cancer Institute (NCI IRB protocol number is 0H00-CN024) and patient data were analyzed anonymously.
DNA samples
DNA was extracted from the frozen tissue samples using a QIAamp Mini DNA extraction kit (Qiagen) according to a slightly modified protocol (the modifications principally consisting of the incorporation of additional wash steps). A single 1 mg aliquot of double-stranded DNA, assayed using the QuBit ds BR assay (Invitrogen) from each of the extractions, was sent to the IBBL in January 2013. IBBL was blinded to the sample identities.
DNA
Using an in-house developed IBBL biospecimen QC assay for authentication of biospecimen identity, all samples were tested for different single-and multi-locus variable numbers of tandem repeats (VNTRs) based on polymerase chain reaction (PCR) amplification of highly polymorphic minisatellite VNTR loci with generation of banding patterns and a specific DNA profile for each sample. For that procedure, the PCR amplification of six minisatellite VNTR loci (Apo-B1: with expected product length 522-909 bp; Col2A1: 600-850 bp; D17S5: 168-1080 bp; D1S80: 400-940 bp; D2S44: 600-> 5000 bp; PAH: 370-760 bp), and one microsatellite locus (GTGN: 10-> 15000 bp) was performed.10,11 After size determination of the amplicons from each loci on an agarose gel using gel-analyzing software (GE HealthCare, ImageQuant TL), the DNA profiles of all samples were compared to each other. 9 samples (each 1 µg) from each of the extractions was provided in January 2013 to IBBL. IBBL was blinded to the sample identities. Using in-house developed IBBL biospecimen quality control (QC) assay for authentication of biospecimen identity all samples were tested for different single-and multi-locus variable numbers of tandem repeats (VNTRs) based on polymerase chain reaction (PCR) amplification of highly polymorphic minisatellite VNTR loci with generation of banding patterns and specific DNA profile for each sample [9] . After size determination of the amplicons from each loci on a agarose gel using gel-analyzing software (GE HealthCare, ImageQuant TL, v.) the DNA profile data of all samples were compared.
Results and Discussion
Mislabelling or cross-contamination may arise from sample handling issues during sample collection or via sample handling errors or pipetting errors at the processing laboratory or biobanks. It may also lead to incorrect assessments of samples and sample mixtures for following applications or analysis [1] . With our current study we report QC assay such as DNA fingerprinting for the biospecimen authentication in expectation that many other laboratories or biobanks can use the information or apply this technique.
Extracted from FFPE tissue DNAs from 9 unknown samples were analyzed by DNA fingerprinting. Among the 9 successfully analysed samples, 3 different profiles were obtained: samples 1 and 5 were identical; samples 2, 3, 7 and 9 were identical; samples 4, 6 and 8 were identical. The IBBL QC assay report was generated and sent to the tissue bank.
DNA fingerprinting showed that there had been no mismatch of samples between individuals either in Institute A or during the extraction procedures at Institute B. The researcher was finally provided with one extra aliquot of DNA from tumour and normal tissue from each of the two cases where duplicate blocks had been extracted, in order to re-run their analyses.
This scenario emphasises the need for detailed and accurate record keeping during processing of biological samples, and the value of independent third-party assessment to identify points at which errors are most likely to have occurred when unexpected results are found from biospecimens from tissue banks. Besides the study has a wider range of applications as exemplified in this case report. This actual case study illustrates the usefulness of the DNA fingerprinting method in biobank QC procedures.
